A gift commitment of $12.5 million to Indiana University School of Medicine from the Vera Bradley Foundation for Breast Cancer will support new research to harness immunotherapy for breast cancer treatment.
Using the nation’s largest COVID-19 data resource, a researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center found the COVID-19 vaccine protected most cancer patients from getting COVID.
Indiana University School of Medicine physician scientist Bryan Schneider, MD is the principal investigator of clinical trial BRE12-158, a randomized clinical study published in the prominent Journal of Clinical Oncology the primary goal of which was to compare survival in women with high-risk (those who did not fully respond to chemotherapy prior to surgery) triple negative breast cancer (TNBC) with a genomically directed therapy versus standard of care.
An Indiana University cancer researcher is leading an $11.4 million grant from the National Cancer Institute in which he and others across the country will work on identifying new treatments for tumors that develop in children, adolescents and adults with a common genetic condition.
In a gesture that defines gratitude and respect spanning more than 23 years, Carmel resident Ruth “Rikki” Kutcher Goldstein has made a $2 million gift to support cancer research at Indiana University School of Medicine.
Indiana University School of Medicine researcher Bryan P. Schneider, MD, is leading a novel nationwide study to better understand how to treat patients with triple-negative breast cancer based on their own unique genetic data.
Researchers in the Department of Pathology and Laboratory Medicine at Indiana University School of Medicine have discovered a novel anti-cancer drug, using a unique approach that has allowed them to target previously undruggable cancerous proteins.